Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.

2.1 Blood Coagulation Analyzers Coagulation analyzers are mainly applied for laboratory tests of thrombosis and hemostasis, which can provide valuable indicators for the diagnosis and differential diagnosis of h..

Sansure Biotech 21% Revenue Growth, Overseas Business Up 60% in H1 2025 Sansure Biotech Inc. announced its 2025 half-year financial results, recording revenue of RMB 869 million, a 21.15% year-on-year in..

Original from: QIAGEN · U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflow · QIAst..

SmartLabs and Sonrai Analytics (Sonrai) today announced a global strategic partnership designed to bring Sonrai's next-generation AI capabilities directly into SmartLabs' network of advanced research centers. Under this agreement, SmartLabs will begin offering Sonrai's AI advanced analytics platform, Sonrai Discovery, to its member companies. Both companies will also develop new laboratory informatics and bespoke AI applications that will integrate experimental and infrastructure data to predict scientific outcomes and accelerate discovery, exclusively to the SmartLabs' network.

Original from: genome web MGI Tech has reported that its revenues for the first half of 2025 dropped 8 percent year over year, mainly due to declining instrument sales. According to a filin..

AliveDx said Tuesday that it has registered its multiplex immunoassay analyzer for autoimmune disease and allergy testing with the US Food and Drug Administration as a Class II device that is exempt from premarket authorization requirements.

SD Biosensor, Inc. (KQ137310), a global leader in in-vitro diagnostics from South Korea, announced that its latent tuberculosis (TB) diagnostic product, STANDARD E TB-Feron ELISA (hereafter STANDARD TB-Feron), has been officially included in the World Health Organization (WHO) recommendation list for TB diagnostics. With this milestone, SD Biosensor strengthens its position in the Interferon-Gamma Release Assay (IGRA) market, marking a shift in the competitive landscape and positioning the company alongside leading global players.

MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Test (Reveal® TP) – the fastest standalone screening device for syphilis in Canada.

Original from: Agilent Highlights · Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core ..

Corewell Health and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, have signed a definitive agreement to enter into a joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

Siemens Healthineers and software developer Carna Health said Tuesday that they have formed a partnership to bring point-of-care chronic kidney disease testing to emerging markets.

2. Current Conditions of Blood Coagulation Analyzers and Reagents in China As indicated by the release of the China Cardiovascular Health and Disease Report 2019, the current number of cardiovascular patients is..

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio.